Although ECT has a longer history than psychotropic medications, few reports have comprehensively quantified and assessed the quality of seizures and the therapeutic effects. For this reason, it has been widely recognized from the earliest days in ECT that it is very important to properly set the stimulation dose and to produce a “sufficiently generalized seizure” in order to obtain efficacy, I have to say that there is little clear ground for compliance. In the clinical practice, the evaluation items proposed by Mankad et al. (â? sufficient convulsive seizure duration, â?¡symbolically synchronized high-frequency slow wave, â?¢postictal suppression, â?£sympathetic nerve excitement) as indicators of effective seizures in ECT Used. However, the problem is that many ECT studies so far have used â? as the main outcome, and few studies have comprehensively examined seizure quality and clinical effects ( â? -â?£). For this reason, we have previously been evaluated empirically and sensory using the Seizure quality scale (SQC) published by Hoyer et al., Which can quantify the quality of seizures comprehensively from 0 to 3 points. The aim is to standardize ECT technology by changing the evaluation scene for seizures, which had many cases. On the homepage of our hospital, an ECT ledger of Excel file that automatically calculates SQC is available for free download (http://www3.kmu.ac.jp/psy/guide/takii.html), and a project called LEBAB is easy to develop for multicenter clinical research worldwide in the future. LEBAB is being tested in Japan. In this presentation, we will introduce our unique approaches using SQC and mention its usefulness. This study has been approved by the Kansai Medical University Ethics Review Committee.